NCT00560612

Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Durham VA Medical Center · Federal
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is: 1) To document the effectiveness and tolerability of paroxetine for the treatment of subthreshold posttraumatic stress disorder (PTSD) in veterans in the early post-deployment period; and 2) To determine the potential efficacy of paroxetine in preventing the progression of anxiety symptoms to PTSD and other anxiety disorders, and improving overall veteran function.

Detailed description

See brief summary

Conditions

• Stress Disorders, Post-Traumatic

Interventions

Type	Name	Description
DRUG	Paroxetine	Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
DRUG	Placebo	Placebo: same as paroxetine (active comparator)

Timeline

• Start date: 2006-01-01
• Primary completion: 2008-07-01
• Completion: 2008-07-01
• First posted: 2007-11-20
• Last updated: 2019-06-18
• Results posted: 2011-01-25

Locations

1 site across 1 country: United States